NEW: Premarket Now Starts at 4AM!

We’re excited to announce the extension of premarket and aftermarket hours! Our members now have access to quotes daily from 4:00 AM to 8:00 PM ET — offering greater flexibility and deeper insights into market trends beyond regular trading hours.

Upgrade to FINVIZ*Elite to access premarket quotes »

GRI

GRI Bio Inc

Apr 04 • 12:10PM ET

1.46

Dollar change +0.02
Percentage change 1.34	%

Healthcare • Biotechnology • USA • NASD

Peers: GILD BMY LLY AZN VRTX AMGN REGN BIIB MRNA IONS

| Held by: VXF

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-203.36	Insider Own	0.05%	Shs Outstand	0.53M	Perf Week	-66.58%
Market Cap	1.06M	Forward P/E	-	EPS next Y	-	Insider Trans	0.00%	Shs Float	0.53M	Perf Month	-78.48%
Income	-10.12M	PEG	-	EPS next Q	-	Inst Own	2.51%	Short Float	3.67%	Perf Quarter	-89.90%
Sales	0.00M	P/S	-	EPS this Y	-	Inst Trans	60.24%	Short Ratio	0.07	Perf Half Y	-73.66%
Book/sh	7.67	P/B	0.19	EPS next Y	-	ROA	-188.80%	Short Interest	0.02M	Perf Year	-98.74%
Cash/sh	6.90	P/C	0.21	EPS next 5Y	-	ROE	-382.57%	52W Range	1.38 - 130.39	Perf YTD	-89.64%
Dividend Est.	-	P/FCF	-	EPS past 5Y	70.23%	ROI	-246.62%	52W High	-98.88%	Beta	-1.50
Dividend TTM	-	Quick Ratio	3.43	Sales past 5Y	-20.00%	Gross Margin	-	52W Low	5.75%	ATR (14)	1.47
Dividend Ex-Date	-	Current Ratio	3.43	EPS Y/Y TTM	98.55%	Oper. Margin	-	RSI (14)	21.02	Volatility	131.63% 41.50%
Employees	4	Debt/Eq	0.03	Sales Y/Y TTM	-	Profit Margin	-	Recom	1.00	Target Price	170.00
Option/Short	No / No	LT Debt/Eq	0.02	EPS Q/Q	98.93%	Payout	-	Rel Volume	3.68	Prev Close	1.44
Sales Surprise	-	EPS Surprise	8.22%	Sales Q/Q	-	Earnings	Feb 26	Avg Volume	269.15K	Price	1.46
SMA20	-72.32%	SMA50	-80.07%	SMA200	-88.69%	Trades		Volume	435,625	Change	1.34%

Date	Action	Analyst	Rating Change	Price Target Change
Dec-09-24	Initiated	H.C. Wainwright	Buy	$10

Apr-02-25 04:05PM	GRI Bio Announces Closing of $5.0 Million Public Offering (GlobeNewswire) -17.33% -13.77%
01:38PM	GRI Stock Down on Public Offering Despite Encouraging IPF Study Data (Zacks)
Apr-01-25 11:15AM	GRI Bio Announces Pricing of $5.0 Million Public Offering (GlobeNewswire) -36.88%
09:00AM	GRI Bio Reports Encouraging Interim 2-Week Safety Results from Ongoing Phase 2a Study of GRI-0621 in Idiopathic Pulmonary Fibrosis ( IPF ) (GlobeNewswire)
Mar-31-25 08:00AM	GRI Bio Bolsters Intellectual Property Portfolio with Granting of Two Global Patents for Europe and Japan (GlobeNewswire) -26.71%
09:05AM	Loading…
Mar-18-25 09:05AM	GRI Bio Participates in a Virtual Investor CEO Connect Segment (GlobeNewswire) +16.01%
Mar-17-25 08:05AM	GRI Bio Reports Full Year 2024 Financial Results and Reiterates Expected Clinical Data Readouts in 2025 for Ongoing Phase 2a Study of GRI-0621 in Idiopathic Pulmonary Fibrosis ( IPF ) (GlobeNewswire) -6.18%
Mar-11-25 08:35AM	GRI Bio Regains Compliance with Nasdaq's Minimum Bid Price Rule (GlobeNewswire) -5.24%
Feb-19-25 04:05PM	GRI Bio Announces Reverse Stock Split (GlobeNewswire) -17.90%
09:00AM	GRI Bio, Inc. Participates in the Virtual Investor Top 5 for '25 On-Demand Conference (GlobeNewswire)
Dec-23-24 09:00AM	GRI Bio Announces European Patent Office Issued a Decision to Grant Notice for Patent Covering GRI-0803 and Its Library of 500+ Proprietary Compounds (GlobeNewswire)
Dec-06-24 08:35AM	GRI Bio to Participate in the Virtual Investor Closing Bell Series (GlobeNewswire) +21.73%
Nov-21-24 08:45AM	GRI Bio Showcases GRI-0621's Potential to Reduce Inflammation, Type 1 Cytokines and Reduce Hepatic Fibrosis in Idiopathic Pulmonary Fibrosis (IPF) (GlobeNewswire) +7.82%
Nov-14-24 04:20PM	GRI Bio Reports Third Quarter 2024 Financial Results and Outlines Progress Towards Clinical Data Readout of GRI-0621 in Ongoing Phase 2a Study for Idiopathic Pulmonary Fibrosis (GlobeNewswire) +9.12% -19.57%
Oct-24-24 08:30AM	GRI Bio Raises a Total of $13.9 Million in Gross Proceeds Since the Beginning of 2024 (GlobeNewswire)
05:35PM	Loading…
Oct-21-24 05:35PM	GRI Bio Announces Exercise of Warrants (GlobeNewswire) +127.59% -26.52%
Oct-16-24 08:45AM	GRI Bio Presents Positive Preclinical Data Demonstrating GRI-0621's Ability to Inhibit Invariant Natural Killer T (iNKT) Cell Activity and Reduce Important Inflammatory and Fibrotic Drivers in Idiopathic Pulmonary Fibrosis (IPF) (GlobeNewswire) +25.43%
Oct-07-24 08:30AM	GRI Bio to Present at the 22nd International Colloquium on Lung and Airway Fibrosis (GlobeNewswire)
Sep-30-24 08:30AM	GRI Bio Granted Japan Patent for Proprietary Natural Killer T (NKT) Cell Modulators for Prevention and Treatment of Inflammatory Conditions (GlobeNewswire) -19.06%
Sep-26-24 08:00AM	GRI Bio Receives Authorization to Conduct Phase 2a Biomarker Study Evaluating GRI-0621 in Australia (GlobeNewswire) +6.00%
Sep-25-24 08:45AM	GRI Bio (NASDAQ: GRI) to Participate in a Virtual Investor CEO Connect Segment (GlobeNewswire)
Sep-18-24 09:00AM	GRI Bio Participates in Virtual Investor KOL Connect Segment (GlobeNewswire)
Sep-05-24 08:45AM	GRI Bio to Present at the H.C. Wainwright 26th Annual Global Investment Conference (GlobeNewswire)
Sep-04-24 08:45AM	GRI Bio to Present at the 2024 European Respiratory Congress (GlobeNewswire)
Aug-14-24 08:05AM	GRI Bio Reports Second Quarter 2024 Financial Results and Provides Corporate Update (GlobeNewswire) -7.57%
Jul-15-24 09:05AM	GRI Bio (NASDAQ: GRI) to Participate in the Virtual Investor Lunch Break Series (GlobeNewswire)
Jul-11-24 09:20AM	GRI Bio (NASDAQ: GRI) Participates in Virtual Investor What This Means Segment (GlobeNewswire)
Jul-08-24 09:05AM	GRI Bio Regains Compliance with Nasdaq (GlobeNewswire)
Jul-02-24 09:05AM	GRI Bio Announces Publication of Positive Preclinical Data from Lead Program GRI-0621 in the American Journal of Respiratory and Critical Care Medicine (GlobeNewswire) -13.68%
Jul-01-24 08:45AM	GRI Bio to Present at the 8th Annual IPF Summit (GlobeNewswire)
04:05PM	Loading…
Jun-28-24 04:05PM	GRI Bio Announces Closing of $4.0 Million Public Offering (GlobeNewswire)
Jun-27-24 09:00AM	GRI Bio Announces Korea Patent Granted for Proprietary Natural Killer T (NKT) Cell Modulators (GlobeNewswire) +7.10%
08:00AM	GRI Bio Announces Pricing of $4 Million Public Offering (GlobeNewswire)
Jun-26-24 08:23AM	Why Is GRI Bio (GRI) Stock Down 29% Today? (InvestorPlace) -38.38%
07:41AM	Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday (InvestorPlace)
Jun-24-24 07:16AM	Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday (InvestorPlace)
Jun-17-24 08:00AM	Final Participating Company Line-Up Announced for the Virtual Investor Pitch Conference Hosted by JTC Team Being Held June 17 - 18, 2024 (ACCESSWIRE)
Jun-14-24 08:05AM	GRI Bio Announces Reverse Stock Split (GlobeNewswire) -11.90%
Jun-12-24 04:15PM	Connect Biopharma Announces New Leadership and Chair of the Board of Directors (GlobeNewswire)
Jun-11-24 09:00AM	GRI Bio (NASDAQ: GRI) to Present at the Virtual Investor Pitch Conference (GlobeNewswire)
Jun-10-24 08:00AM	JTC Team Announces Participating Company Line-Up for the Virtual Investor Pitch Conference on June 17-18, 2024 (ACCESSWIRE)
May-23-24 10:30AM	GRI Bio (NASDAQ: GRI) Participates in Virtual Investor CEO Connect (ACCESSWIRE) -9.03%
May-22-24 09:15AM	GRI Bio (NASDAQ: GRI) Participates in Virtual Investor What This Means Segment Highlighting Positive Preclinical Data from Idiopathic Pulmonary Fibrosis (IPF) and Systemic Lupus Erythematosus (SLE) Programs (GlobeNewswire) +9.53%
May-21-24 08:35AM	GRI Bio Presents Positive Preclinical Data from Pipeline of NKT Cell Modulators in Development for the Treatment of Systemic Lupus Erythematosus (SLE) (GlobeNewswire)
May-20-24 08:45AM	GRI Bio Presents Positive Preclinical Data Demonstrating Lead Program GRI-0621 Reduces the Important Inflammatory and Fibrotic Drivers in Idiopathic Pulmonary Fibrosis (IPF) (GlobeNewswire)
May-14-24 09:05AM	GRI Bio to Present at Alliance Global Partner's 2024 Healthcare Company Showcase (GlobeNewswire)
May-13-24 10:54AM	GRI Stock Earnings: GRI Bio Reported Results for Q1 2024 (InvestorPlace)
08:00AM	GRI Bio Reports First Quarter 2024 Financial Results and Provides Corporate Update (GlobeNewswire)
Apr-29-24 08:45AM	GRI Bio Announces Abstracts Accepted for Presentation at the 14th International Congress on Autoimmunity (GlobeNewswire)
Apr-25-24 09:15AM	GRI Bio to Present at LIVE! with Webull Corporate Connect: Virtual Biotech Investment Webinar (GlobeNewswire)
Apr-16-24 08:35AM	GRI Bio Expands Intellectual Property Protection for Proprietary Natural Killer T (NKT) Cell Modulators with Issuance of Korea Patent (GlobeNewswire)
Apr-08-24 08:35AM	GRI Bio Announces Abstract Accepted for Poster Presentation at the 2024 American Thoracic Society International Conference (GlobeNewswire) +5.16%
Apr-01-24 07:35AM	GRI Bio Reports Full Year 2023 Financial Results and Provides Corporate Update (GlobeNewswire)
Mar-28-24 09:00AM	GRI Bio to Present at the MedInvest Biotech & Pharma Investor Conference (GlobeNewswire)
Mar-14-24 08:45AM	GRI Bio Announces Notice of Allowance for Canadian Patent Covering Proprietary Natural Killer T (NKT) Cell Modulators (GlobeNewswire)
Mar-04-24 08:30AM	GRI Bio Receives MHRA Authorization to Conduct Phase 2a Biomarker Study Evaluating GRI-0621 in the United Kingdom (GlobeNewswire)
Feb-02-24 08:55AM	Why Is GRI Bio (GRI) Stock Down 21% Today? (InvestorPlace) -26.15%
08:00AM	GRI Bio Announces Pricing of $5.5 Million Public Offering (GlobeNewswire)
Jan-26-24 08:05AM	GRI Bio Announces Reverse Stock Split (GlobeNewswire) +5.62%
Dec-06-23 01:47PM	GRI Bio begins patent enrollment for Phase 2a study of GRI-0621 for IPF treatment (News Direct) -5.98%
Dec-05-23 09:05AM	GRI Bio Commences Patient Enrollment in Phase 2a Biomarker Study Evaluating Lead Program GRI-0621 for the Treatment of Idiopathic Pulmonary Fibrosis ( IPF ) (GlobeNewswire) -25.39%
Nov-27-23 08:35AM	GRI Bio (NASDAQ: GRI) Announces FDA Clearance of IND for Lead Program GRI-0621, a Type 1 Invariant NKT ( iNKT ) Antagonist for the Treatment of Idiopathic Pulmonary Fibrosis ( IPF ) (GlobeNewswire) -13.33%
Nov-15-23 08:05AM	GRI Bio (NASDAQ: GRI) Reports Third Quarter 2023 Financial Results and Provides Corporate Update (GlobeNewswire) -6.49%
Oct-31-23 08:45AM	GRI Bio Presents Data Supporting Innovative Pipeline of NKT Cell Modulators for the Treatment of High-Value Inflammatory, Fibrotic and Autoimmune Diseases (GlobeNewswire) +5.17%
Oct-19-23 08:45AM	GRI Bio Presents Translational Data Demonstrating Connection Between NKT Cells and the Pathogenesis of Idiopathic Pulmonary Fibrosis (IPF) at the 2023 Pittsburgh-Ireland International Lung Conference (GlobeNewswire)
Oct-18-23 10:00AM	JTC Team Announces Presenting Company Line Up for the Virtual Investor Ask the CEO Conference Being Held October 24-25, 2023 (ACCESSWIRE) -5.47%
Oct-17-23 08:35AM	GRI Bio Announces Partnership with the Respiratory Translational Research Collaboration to Advance Leading NKT Regulation Technology Targeting Earlier in the Inflammatory Cascade to Modulate Disease Progression (GlobeNewswire) -14.09%
Oct-11-23 09:05AM	GRI Bio (NASDAQ: GRI) to Participate in the Virtual Investor Ask the CEO Conference (GlobeNewswire)
Oct-05-23 08:45AM	GRI Bio Announces Publication of Comprehensive Invariant NKT (iNKT) Cell Review in Frontiers in Immunology Demonstrating a Key Role of Type 1 iNKT Cells in Modulating Various Fibrotic Conditions (GlobeNewswire)
Sep-29-23 09:00AM	September Is Pulmonary Fibrosis Awareness Month: Heres What One Company Is Doing To Develop A Treatment For This Deadly Disease (ACCESSWIRE) -6.91%
Sep-06-23 09:05AM	GRI Bio to Present at the H.C. Wainwright 25th Annual Global Investment Conference (GlobeNewswire)
Sep-01-23 09:15AM	IPF Has A 0% Survival Rate Without Lung Transplant And A Median Survival Time Of 2-5 Years From Diagnosis - Could GRI-0621 Be The Solution? (ACCESSWIRE)
Aug-29-23 11:06AM	GRI Bio Engages B2i Digital to Deploy Cutting-Edge Engagement Campaign (Newsfile) +5.74%
Aug-25-23 09:00AM	GRI Bio Is Bringing Hope To Patients With Idiopathic Pulmonary Fibrosis And Lupus (ACCESSWIRE) -12.26%
Aug-23-23 09:00AM	GRI Bio Enters into Asset Purchase Agreement with Aardvark Therapeutics, Inc. for the Sale of Legacy Asset, ADAIR (GlobeNewswire) -25.75%
Aug-16-23 12:00PM	JTC Team Announces the Launch of the Virtual Investor "What This Means" On Demand Video Series (ACCESSWIRE)
Aug-14-23 08:05AM	GRI Bio (NASDAQ: GRI) Reports Second Quarter 2023 Financial Results and Provides Corporate Update (GlobeNewswire)
Aug-07-23 08:35AM	GRI Bio Presents Encouraging Preclinical Data Indicating Oral Administration of GRI-0803 Inhibited Lupus Nephritis and Significantly Improved Overall Survival in Animal Models (GlobeNewswire)
Aug-03-23 08:30AM	GRI Bio (NASDAQ: GRI) to Present at Benzingas Virtual Biotech Conference (GlobeNewswire)
Jul-26-23 11:15AM	JTC Team to Host Two Virtual Investor Spotlight Events on Thursday, July 27th (ACCESSWIRE)
Jul-24-23 09:00AM	GRI Bio (NASDAQ: GRI) to Present at the Virtual Investor The GRI Opportunity Spotlight Event (GlobeNewswire)
Jul-05-23 08:45AM	GRI Bio, Inc. (NASDAQ: GRI) to Participate in the Virtual Investor Summer Spotlight Series (GlobeNewswire)
Jun-27-23 08:45AM	GRI Bio (NASDAQ: GRI) Bolsters Patent Portfolio (GlobeNewswire)
Jun-15-23 08:45AM	GRI Bio (NASDAQ: GRI) to Participate in the Healthcare Virtual Conference Presented by Maxim Group LLC and Hosted by M-Vest (GlobeNewswire) -7.41%
Jun-13-23 08:35AM	GRI Bio (NASDAQ: GRI) Announces Corporate Rebranding and Launch of New Website (GlobeNewswire)
May-22-23 08:45AM	GRI Bio (NASDAQ: GRI) Provides Business Outlook and Highlights Upcoming Milestones for Innovative Pipeline of NKT Cell Modulators (GlobeNewswire)
Apr-27-23 09:05AM	GRI Bio (NASDAQ: GRI) to Present at the Virtual Investor New to the Street Event (GlobeNewswire) +17.98%
Apr-25-23 08:45AM	GRI Bio (NASDAQ: GRI) Announces Appointment of Leanne Kelly as Chief Financial Officer (GlobeNewswire) -5.53%

GRI Bio, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of therapies for inflammatory, fibrotic, and autoimmune diseases. It focuses on its lead program, GRI-0621, an inhibitor of type 1 invariant Natural Killer T (iNKT) cell activity and is being developed as a novel oral therapeutic for the treatment of idiopathic pulmonary fibrosis. The company was founded by Vipin Kumar Chaturvedi in May 2009 and is headquartered in La Jolla, CA.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

GRI

GRI Bio Inc

Upgrade your FINVIZ experience